Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de Fernandez, E. P.
Right arrow Articles by Tarbit, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Fernandez, E. P.
Right arrow Articles by Tarbit, M. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1986) 18, 261-270
© 1986 The British Society for Antimicrobial Chemotherapy

research-article

Treatment of cryptococcal meningitis in mice with fluconazole

Elsa Palou de Fernandez*,{dagger}, Maria Mercedes Patino*,{dagger}, John R. Graybill*,{dagger}, and Michael H. Tarbit{ddagger}

*Audie Murphy Memorial Veterans Administration Hospital San Antonio, Texas, U.S.A. {dagger}University of Texas Health Science Center San Antonio, Texas, U.S.A. {ddagger}Pfizer Central Research Sandwich, England

accepted 10 December 1985

Correspondence to: Dr Graybill at the Veterans Administration Hospital (111F), 7400 Merton Minter Blvd, San Antonio, 78284, U.S.A.

Fluconazole is a recently developed triazole with activity in vitro against Cryptococcus neoformans, water solubility, and excellent oral absorption. We compared fluconazole in murine cryptococcosis with ketoconazole and amphotericin B. Fluconazole was highly effective in suppressing cryptococcosis in mice challenged by the intravenous and intranasal routes, and was comparable with the other two drugs in its protective capacity. However, fluconazole was superior to ketoconazole and comparable with amphotericin B after intracerebral challenge. Fluconazole may warrant clinical evaluation in cryptococcosis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
J. Y. Ju, C. Polhamus, K. A. Marr, S. M. Holland, and J. E. Bennett
Efficacies of Fluconazole, Caspofungin, and Amphotericin B in Candida glabrata-Infected p47phox-/- Knockout Mice
Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1240 - 1245.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
O. Lortholary, M. Nicolas, S. Soreda, L. Improvisi, O. Ronin, O. Petitjean, B. Dupont, M. Tod, and F. Dromer
Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing
J. Antimicrob. Chemother., June 1, 1999; 43(6): 817 - 824.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. K. Najvar, R. Bocanegra, and J. R. Graybill
An Alternative Animal Model for Comparison of Treatments for Cryptococcal Meningitis
Antimicrob. Agents Chemother., February 1, 1999; 43(2): 413 - 414.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
W. E. Dismukes
Azole Antifungal Drugs: Old and New
Ann Intern Med, August 1, 1988; 109(3): 177 - 179.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.